Associated Papers
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM et al.
Cancer Biology & Therapy, 2017
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Chahardouli B et al.
Hematology (amsterdam, Netherlands), 2013
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Iqbal Z et al.
Plos One, 2013
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Cortes J et al.
Blood, 2007
High-throughput, sensitive and quantitative assay for the detection of BCR-ABL kinase domain mutations.
Vivante A et al.
Leukemia, 2007
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Gruber FX et al.
Leukemia, 2005
Select a paper to view details